Urinary N-Acetyl-Beta-D-Glucosaminidase levels predict immunoglobulin a nephropathy remission status

BMC Nephrology

Table 3 Multivariable logistic analyses of urinary NAG and serum CysC for predicting risk of IgAN progression

	Cut Points	Remission failure %	Unadjusted OR (95% Cl); P	Adjusted OR (95% Cl)
	Cut Points	Remission failure %	Unadjusted OR (95% Cl); P	Model 1^a, P	Model 2^b, P	Model 3^c, P
Urinary NAG (U/g Cr)
T1 + T2 (n = 142)	≤ 22.32	9.2	1.0 (referent)	1.0 (referent)	1.0 (referent)	1.0 (referent)
T3 (n = 71)	> 22.32	42.3	7.26 (3.47–15.21); <0.001	7.18 (3.39–15.22); <0.001	4.41 (1.94–9.99); <0.001	4.32 (1.87–9.96); 0.001
Serum CysC (mg/L)
T1 + T2 (n = 142)	≤ 1.34	13.4	1.0 (referent)	1.0 (referent)	1.0 (referent)	1.0 (referent)
T3 (n = 71)	> 1.34	33.8	3.31 (1.66–6.59); 0.001	4.33 (2.00-9.36); < 0.001	1.42 (0.43–4.69); 0.561	1.32 (0.39–4.46); 0.655

Abbreviations: Cl, confidence interval; Cr, creatinine; OR, Odds ratio; BMI, body mass index; eGFR, estimated glomerular filtration rate; MAP, mean arterial blood pressure; MEST-C, histologic score based on mesangial hypercellularity, the presence of endocapillary proliferation, segmental glomerulosclerosis/adhesion, and severity of tubular atrophy/interstitial fibrosis, and crescents formation; T, tertile
^aModel 1 adjusted for age, sex, MAP, BMI
^bModel 2 adjusted for covariates in model 1 plus 24-hour proteinuria, eGFR and Oxford MEST-C score
^cModel 3 adjusted for covariates in model 1 and 2 plus use of renin-angiotensin system inhibition and immunosuppression during follow-up

ISSN: 1471-2369